<b>Gapping up <br/>In reaction to strong earnings/guidance/Dec SSS:</b><br/><br/>ZUMZ +17.1%, DPW +7.1%, RPM +3.5%, BLFS +1.7%, RECN +1.6%, CVS +1.2%, COST +1%<br/><b>Other news:</b><br/><br/>CNET +100.9% (announces strategic partnership with Jingtum Technology), COGT +40% (announce strategic alliance to combine analytics and intelligence with leading blockchain technology), SKLN +35.4% (Skyline Medical reports sale of 5 STREAMWAY Systems in Q4; 6 units have been booked for sale in January 2018), APOP +33.4% (announces breakthrough clinical results), TOPS +26.5% (extended the time charter agreements with Stena Bulk AB; total gross revenue backlog for the fixed charter period of all operating fleet stands at about $131 million), APHB +19.6% (Ampliphi Biosciences announces topline results for the first seven patients treated under its ongoing single-patient expanded access program; 'six patients, 86%, achieving treatment success' ), CCXI +18.7% (announces conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA), CLNT +11.5% (enters into exclusivity agreement with Channel Power for potential acquisition of Touch Media), DCIX +7% (Trend Discovery discloses increased passive stake), DOVA +6% (Dova Pharmaceuticals provides update on development strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia), MNTA +5.7% (Momenta Pharma and Mylan (MYL) announced the development strategy for M710, a proposed biosimilar to EYLEA injection; cos plan to initiate a pivotal clinical trial in patients in 1H18), OMF +5.1% (Apollo Global Management (APO) buying FIG stake, according to Reuters exclusive), ARCT +4.1% (Arcturus Therapeutics and CureVac enter into a broad strategic collaboration), OSTK +3.4% (CEO Byrne and Hernando de Soto enter MOU to form blockchain company focused on property rights), MCRB +3.3% (announces initial results from its Phase 1b study of SER-287), AMD +3.1% (seeing modest bounce in after hours/pre-mkt trade after company claims 'near-zero risk' to its chips), BOLD +1.9% (announces 'positive' interim data from the first dose cohort of ASPIRO in patients with X-Linked Myotubular Myopathy ), REXX +1.8% (after jumping 50% higher), NMFC +1.8% (authorizes an extension of its $50 mln share repurchase program), SAND +1.6% (reported record gold equivalent production in 2017 and the sale of US$18 million of securities of Equinox Gold ), SSW +1.3% (announces letter of intent for potential $250 mln Unsecured 5.50% Debenture and Warrant Investment from Fairfax Financial Holdings Limited), . <br/><b>Analyst comments:</b><br/><br/>DPZ +3.3% (upgraded to Outperform from Neutral at Credit Suisse; upgraded to Outperform from Perform at Oppenheimer)<br/>WWE +3.3% (upgraded to Outperform from Market Perform at Wells Fargo)<br/>WIX +2.9% (upgraded to Strong Buy at Raymond James )<br/>CNHI +2.7% (upgraded to Buy from Hold at Deutsche Bank)<br/>NUVA +2.4% (upgraded to Buy at Needham)<br/>HOLX +2.3% (upgraded to Buy from Neutral at BofA/Merrill)<br/>TEVA +2% (upgraded to Buy from Neutral at Citigroup)<br/>MRO +1.6% (upgraded to Buy from Neutral at BofA/Merrill)<br/>SRPT +1.5% (initiated with a Buy at Janney)<br/>FFIV +0.9% (upgraded to Outperform from Market Perform at BMO Capital)<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/><br/>LB -9.2%, RAD -6.2%, LNDC -5.1%, TSLA -3.4%, (Tesla reports Q4 deliveries of 29,870 vehicles -- 15,200 were Model S, 13,120 were Model X, and 1,550 were Model 3), M -3.3%, JCP -2.7%, WBA -0.7%<br/><b>Other news:</b><br/><br/>OVAS -4.8% (OvaScience reports Initial Safety Data from Phase 1 Study of OvaPrime, is reducing headcount by approximately 50%, and appoints James Lillie, Ph.D., as Chief Scientific Officer)<br/>ARE -4.2% (prices 6 mln share offering at $123.50)<br/>INSM -3% (announces additional data from ALIS )<br/>CCCR -2.8% (receives notice from Sorghum Investment that Share Exchange Agreement is being terminated)<br/>RENN -2.5% (after jumping 50% higher)<br/>TMHC -2.3% (commences offering of 11 mln shares of Class A common stock and increases previously announced stock repurchase program )<br/>INTC -2% (following call to discuss reports of new security research findings)<br/>WBA -1.2% (following RAD earnings/update)<br/>ATRA -0.8% (prices 7 mln shares of common stock at $18.25 per share)<br/><b>Analyst comments: </b><br/><br/>ROKU -7.3% (downgraded to Underweight from Equal-Weight at Morgan Stanley)<br/>SNAP -3.7% (downgraded to Underperform at Cowen) <br/>RECN 2% (downgraded to Underweight from Neutral at JP Morgan),<br/>AVP -1.4% (downgraded to Underperform from Neutral at BofA/Merrill)<br/>WLH -1.4% (downgraded to Neutral from Buy at Citigroup)<br/>WDC -1.2% (downgraded to Market Perform from Outperform at BMO Capital)<br/>SNDR -1.2% (downgraded to Neutral from Buy at Citigroup)<br/><br/>Briefing.com